Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply Correspondence
| Authors: | Pires da Silva, I.; Ahmed, T.; Reijers, I. L. M.; Warner, A. B.; Randall Patrinely, J.; Serra-Bellver, P.; Allayous, C.; Mangana, J.; Zimmer, L.; Trojaniello, C.; Klein, O.; Gerard, C. L.; Michielin, O.; Haydon, A.; Ascierto, P. A.; Carlino, M. S.; Lebbe, C.; Lorigan, P.; Johnson, D. B.; Sandhu, S.; Lo, S. N.; Menzies, A. M.; Long, G. V. |
| Title: | Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply |
| Journal Title: | Lancet Oncology |
| Volume: | 22 |
| Issue: | 8 |
| ISSN: | 1470-2045 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2021-08-01 |
| Start Page: | e343 |
| End Page: | e344 |
| Language: | English |
| DOI: | 10.1016/s1470-2045(21)00419-8 |
| PROVIDER: | scopus |
| PUBMED: | 34339647 |
| DOI/URL: | |
| Notes: | Letter -- Export Date: 1 September 2021 -- Source: Scopus |
